MOUNTAINEER: Tucatinib Plus Trastuzumab Active in Metastatic Colorectal Cancer
In the phase II MOUNTAINEER trial, tucatinib in combination with trastuzumab produced durable responses in patients with previously treated...
Global Phase III FRESCO-2 Study Has Met Its Primary Endpoint in Evaluation of Fruquintinib for Metastatic Colorectal Cancer
The pivotal global phase III FRESCO-2 trial evaluating the investigational use of fruquintinib met its primary endpoint of overall survival in...
5-Year Outcomes With Laparoscopic vs Open Distal Gastrectomy in Locally Advanced Gastric Cancer
In the 5-year follow-up of the Korean KLASS-02 trial reported in JAMA Surgery, Son et al found similar 5-year overall survival and relapse-free survival...
FDA Approves Darolutamide for Metastatic Hormone-Sensitive Prostate Cancer
On August 5, the U.S. Food and Drug Administration approved darolutamide (Nubeqa) tablets in combination with docetaxel for adult patients...
ASCO Coronavirus Resources
As the coronavirus (COVID-19) continues to spread, ASCO is committed to providing the most current information and resources to its members and the larger oncology...
Bruce Cheson: Death and Clinical Trials in the Plague Years
Daniel Vorobiof and Irad Deutsch: The Value of Managing Aggregated Data From Patients’ Online Communities
Kathleen Moore: ARIEL4 Confirms Rucaparib’s Efficacy in Recurrent, BRCA-Mutated Ovarian Cancer: Does It Tell Us Anything New?
Sergey Kozhukhov, and colleagues on Cancer and War in Ukraine: How the World Can Help Win This Battle
Ronald DePinho: Basic Research Enterprise Needs Adequate Funding to Foster Treatment Innovation
Sponsored Content
Sponsored by Pharmacyclics
Evolving Role of BTK Inhibitors in the Front-Line Treatment of Chronic Lymphocytic Leukemia
Sponsored by Pfizer Medical Affairs
First-Line Treatment of ALK-Positive Metastatic NSCLC
Sponsored by Pfizer Medical Affairs
Considerations in the Front-Line Treatment of Hormone Receptor–Positive/HER2-Negative Advanced Breast Cancer
Nivolumab Plus Chemotherapy and Nivolumab Plus Ipilimumab as First-Line Treatment for Patients With Advanced Esophageal Cancer
The first results from the phase III CheckMate 648 study represent significant progress in the treatment of patients with advanced esophageal squamous cell carcinoma. The trial evaluated first-line treatment with nivolumab plus chemotherapy or nivolumab plus ipilimumab in patients with advanced...
Impact of Genes on Total Number and Type of Nevi
A study by Duffy et al in the Journal of Investigative Dermatology reported on specific gene variations affecting the number and types of moles on the body and their role in causing skin cancer. “The goal was to investigate the genetic underpinnings of different mole classes, or...
APOLLO Trial: Addition of Subcutaneous Daratumumab to Pomalidomide/Dexamethasone in Previously Treated Patients With Multiple Myeloma
As reported in The Lancet Oncology by Meletios A. Dimopoulos, MD, and colleagues, the phase III APOLLO trial has shown significantly improved progression-free survival with the addition of subcutaneous daratumumab to pomalidomide/dexamethasone in patients with previously treated multiple myeloma....
Transoral Surgery Followed by Lower-Dose Radiation in Patients With HPV-Associated Oropharyngeal Cancer at Intermediate Risk of Recurrence
The phase II E3311 trial offers new information about using reduced-intensity treatment in patients with human papillomavirus (HPV)-associated oropharyngeal cancer who are at intermediate risk of recurrence. These findings were presented by Robert L. Ferris, MD, PhD, and colleagues during the 2021...
Gemcitabine/Eribulin in Cisplatin-Ineligible Metastatic Urothelial Carcinoma
In the final analysis from a phase II California Cancer Consortium trial (NCI-9653) reported in the Journal of Clinical Oncology, Sadeghi et al found the combination of gemcitabine and eribulin showed activity in cisplatin-ineligible patients with metastatic urothelial carcinoma. Study Details...
Predictors of Emergency Department Visits After a New Diagnosis of Cancer
In a retrospective cohort study reported in JCO Oncology Practice, Hong et al found that prior frequent emergency department use was the strongest predictor of postdiagnosis emergency department visits among patients with a new diagnosis of cancer. Study Details The study involved data from...
Deintensified Chemoradiotherapy for HPV-Associated Oropharyngeal Squamous Cell Carcinoma
In a phase II trial reported in the Journal of Clinical Oncology, Chera et al found that deintensified chemoradiotherapy produced favorable outcomes in human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma. Study Details In the multicenter trial, 114 patients were recruited...
